AstraZeneca has announced that its Imfinzi® (durvalumab) and Lynparza® (olaparib) combination has been approved in the EU as treatment for certain patients with primary advanced or recurrent endometrial cancer. This approval follows the recommendation by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which was based on DUO-E Phase II results last month.
AstraZeneca’s report also mentions that regulatory submissions for Imfinzi® and Lynparza® are currently under review in Japan and several other countries based on the DUO-E trial. The FDA also recently approved Imfinzi® (durvalumab) plus chemotherapy for dMMR patients with primary advanced or recurrent endometrial cancer.